Ernexa Therapeutics Inc. — fact timeline

Ernexa Therapeutics Inc.: Effected a 1-for-25 reverse stock split of common stock via certificate of amendment to the Restated Certificate of Incorporation (effective 2026-05-04).

“On May 1, 2026, Ernexa Therapeutics Inc. (the “Company”), filed a certificate of amendment (the “ Certificate of Amendment ”) to the Company’s Restated Certificate of Incorporation, as amended with the Secretary of State of Delaware to effect a reverse stock split of the Company’s common stock at a ratio of 1-for-25 (the “ Reverse Stock Split ”).”

Ernexa Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv)).

“March 18, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “ Company ”, “ we ”, “ us ”, or “ our ”), received a written notice (the “ Notice ”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Nasdaq staff (the “ Staff ”) determined that the Company’s common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, in violation of Nasdaq Listing Rule 5550(a)(2) (the “ Rule ”). While companies are typically afforded a 180-calendar day compliance period, as specified under Nasdaq L”

Ernexa Therapeutics Inc. entered into Warrant Agent Agreement with Computershare Inc. and Computershare Trust Company, N.A. (effective 2026-02-10).

“On February 10, 2026, the Company also entered into a Warrant Agent Agreement (the “Warrant Agent Agreement”) with Computershare Inc. and Computershare Trust Company, N.A. (collectively, “Computershare”),”

Ernexa Therapeutics Inc. entered into Purchase Agreement with certain investors (effective 2026-02-06).

“In connection with the Offering, the Company also entered into a securities purchase agreement (each, a “Purchase Agreement”) with certain investors who purchased Shares, Pre-Funded Warrants and Warrants in the Offering.”

Ernexa Therapeutics Inc. entered into Placement Agency Agreement with Brookline Capital Markets, a division of Arcadia Securities, LLC (effective 2026-02-06).

“On February 6, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Brookline Capital Markets, a division of Arcadia Securities, LLC”

Ernexa Therapeutics Inc. engaged Haskell & White LLP as its auditor.

“he statements made by the Company in this Item 4.01 insofar as they relate to Grant Thornton’s audit services and engagement as the Company’s independent registered public accounting firm. Grant Thornton has furnished a letter addressed to the SEC, a copy of which is attached hereto as Exhibit 16.1. (b) Appointment of New Independent Registered Public Accounting Firm On July 1, 2025, the Company engaged Haskell & White LLP (“Haskell & White”) as the Company’s independent registered”

Ernexa Therapeutics Inc. dismissed Grant Thornton LLP as its auditor.

“ismissal of Former Independent Registered Public Accounting Firm On June 30, 2025, Ernexa Therapeutics Inc. (the “Company) dismissed Grant Thornton LLP (“Grant Thornton”) as the Company’s independent registered public accounting firm effective immediately.”

Ernexa Therapeutics Inc.: Reverse stock split of common stock at 1-for-15 ratio via certificate of amendment to Restated Certificate of Incorporation (effective 2025-06-12).

“Effective June 12, 2025, Ernexa Therapeutics Inc. (the “Company”), filed a certificate of amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Amended COI”) with the Secretary of State of Delaware to effect a reverse stock split of the Company’s common stock, at a ratio of 1-for-15.”

Ernexa Therapeutics Inc.: Allowed stockholder action by written consent in addition to meetings (effective 2025-06-02).

“Additionally, effectively June 2, 2025, the Company filed a certificate of amendment to its Amended COI with the Secretary of State of Delaware to allow for action required or permitted to be taken by stockholders of the Company to be effected by written consent of such stockholders in addition to duly called annual or special meetings of such stockholders.”

Ernexa Therapeutics Inc.: Increased authorized common stock from 100,000,000 to 150,000,000 (effective 2025-06-02).

“Effective June 2, 2025, Ernexa Therapeutics Inc. (the “Company”), filed a certificate of amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Amended COI”) with the Secretary of State of Delaware to increase the authorized shares of its common stock from 100,000,000 to 150,000,000.”

Ernexa Therapeutics Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“January 6, 2025, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that for the last 35 consecu”

Elena Ratner was appointed as Director at Ernexa Therapeutics Inc..

“On January 6, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Dr. Elena Ratner to the Board effective January 7, 2025.”

Dorothy Clarke resigned as Director at Ernexa Therapeutics Inc..

“On January 3, 2025, Dorothy Clarke submitted her resignation from the Board of Directors (the “ Board ”) of the Company, effective at 11:59 p.m. Eastern Time on January 6, 2025.”

Ernexa Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 30, 2024, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closi”